论文部分内容阅读
In persons with type 2 diabetes mellitus (PWD2), therapeutic potential of continuous subcutaneous insulin infusion (CSII) is yet to be specified.The purpose of our open label on-going trial is to compare development of HbA1c concentration, daily insulin dose and BMI in PWD2 using CSII.Since the year 2000, over 50 poorly controlled Cpeptide positive PWD2 previously on intensive plasma glucose selfmonitoring and supplementary insulin therapy,were put on CSII using various models of insulin pumps, and checked in 1-to 3-month intervals as before.